Lexicon Pharmaceuticals (LXRX)
Market Price (7/25/2026): $0 | Market Cap: $-Sector: Health Care | Industry: Biotechnology
Lexicon Pharmaceuticals (LXRX)
Market Price (7/25/2026): $0Market Cap: $-Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -12% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 123% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -20%, 3Y Excs Rtn is -57% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.03 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -35% Stock price has recently run up significantly12M Rtn12 month market price return is 103% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -56%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -56% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.1% Key risksLXRX key risks include [1] significant cash burn and high bankruptcy risk raising solvency concerns, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -12% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 123% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -20%, 3Y Excs Rtn is -57% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.03 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -35% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 103% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -56%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -56% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.1% |
| Key risksLXRX key risks include [1] significant cash burn and high bankruptcy risk raising solvency concerns, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Lexicon Pharmaceuticals (LXRX) stock has gained about 45% since 3/31/2026 because of the following key factors:
1. Lexicon Pharmaceuticals reported robust fiscal Q1 2026 financial results and strengthened its financial position. The company announced total revenues of $21.1 million for fiscal Q1 2026 (ended March 31, 2026), a significant increase from $1.3 million in fiscal Q1 2025, primarily driven by two $10 million milestone payments from its licensing agreement with Novo Nordisk. Concurrently, Lexicon significantly reduced its net loss to $1.0 million, or less than $0.01 per share, in fiscal Q1 2026, a notable improvement from a $25.3 million loss, or $0.07 per share, in the prior year. The company also announced a new $100 million loan facility with Hercules Capital in May 2026, with an initial $55 million tranche funded at closing, reinforcing its balance sheet with $199.7 million in cash, cash equivalents, short-term investments, and restricted cash as of March 31, 2026.
2. Significant advancements in key pipeline programs, particularly with LX9851 and Novo Nordisk, fueled investor optimism. In March 2026, Novo Nordisk initiated a Phase 1 study for LX9851, an oral obesity drug candidate, triggering a $10 million milestone payment to Lexicon Pharmaceuticals. This partnership holds substantial future potential, with Lexicon eligible for an additional $10 million milestone later in 2026 and up to an aggregate of $1 billion in development, regulatory, and sales milestone payments, plus tiered royalties. Additionally, Lexicon anticipated the resubmission of its New Drug Application (NDA) for ZYNQUISTA® in type 1 diabetes in mid-2026, with potential for U.S. regulatory approval within the year. Progress was also reported for SONATA-HCM, a pivotal Phase 3 study for sotagliflozin in hypertrophic cardiomyopathy, with enrollment expected to complete by mid-2026.
Show more
Lexicon Pharmaceuticals (LXRX) stock has gained about 45% since 3/31/2026 because of the following key factors:
1. Lexicon Pharmaceuticals reported robust fiscal Q1 2026 financial results and strengthened its financial position. The company announced total revenues of $21.1 million for fiscal Q1 2026 (ended March 31, 2026), a significant increase from $1.3 million in fiscal Q1 2025, primarily driven by two $10 million milestone payments from its licensing agreement with Novo Nordisk. Concurrently, Lexicon significantly reduced its net loss to $1.0 million, or less than $0.01 per share, in fiscal Q1 2026, a notable improvement from a $25.3 million loss, or $0.07 per share, in the prior year. The company also announced a new $100 million loan facility with Hercules Capital in May 2026, with an initial $55 million tranche funded at closing, reinforcing its balance sheet with $199.7 million in cash, cash equivalents, short-term investments, and restricted cash as of March 31, 2026.
2. Significant advancements in key pipeline programs, particularly with LX9851 and Novo Nordisk, fueled investor optimism. In March 2026, Novo Nordisk initiated a Phase 1 study for LX9851, an oral obesity drug candidate, triggering a $10 million milestone payment to Lexicon Pharmaceuticals. This partnership holds substantial future potential, with Lexicon eligible for an additional $10 million milestone later in 2026 and up to an aggregate of $1 billion in development, regulatory, and sales milestone payments, plus tiered royalties. Additionally, Lexicon anticipated the resubmission of its New Drug Application (NDA) for ZYNQUISTA® in type 1 diabetes in mid-2026, with potential for U.S. regulatory approval within the year. Progress was also reported for SONATA-HCM, a pivotal Phase 3 study for sotagliflozin in hypertrophic cardiomyopathy, with enrollment expected to complete by mid-2026.
3. Inclusion in the Russell Indexes increased institutional investor interest and trading liquidity. Effective June 27, 2026, Lexicon Pharmaceuticals was added to the Russell 2000, Russell 3000E, and Russell 2500 Growth indexes. This inclusion typically leads to increased buying activity from passive funds that track these benchmarks, thereby enhancing the stock's visibility, liquidity, and broader institutional ownership.
4. Favorable analyst sentiment and raised price targets contributed to positive momentum. Throughout the specified period, financial analysts maintained or upgraded their ratings for Lexicon Pharmaceuticals, with a consensus ranging from "Strong Buy" to "Moderate Buy." Average price targets were set between $3.85 and $4.55, with a high forecast of $6.00, implying significant upside potential from the stock's prevailing price levels in Q2 2026. For instance, Citi maintained a Buy rating and raised its price target to $3.10 from $2.30 in May 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
The 46.8% change in LXRX stock from 3/31/2026 to 7/24/2026 was primarily driven by a 39.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.56 | 2.29 | 46.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 50 | 70 | 39.8% |
| P/S Multiple | 11.4 | 13.2 | 15.6% |
| Shares Outstanding (Mil) | 363 | 400 | -9.2% |
| Cumulative Contribution | 46.8% |
Market Drivers
3/31/2026 to 7/24/2026| Return | Correlation | |
|---|---|---|
| LXRX | 46.8% | |
| Market (SPY) | 13.6% | 8.9% |
| Sector (XLV) | 10.9% | 28.8% |
Fundamental Drivers
The 99.1% change in LXRX stock from 12/31/2025 to 7/24/2026 was primarily driven by a 123.2% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.15 | 2.29 | 99.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 71 | 70 | -1.7% |
| P/S Multiple | 5.9 | 13.2 | 123.2% |
| Shares Outstanding (Mil) | 363 | 400 | -9.2% |
| Cumulative Contribution | 99.1% |
Market Drivers
12/31/2025 to 7/24/2026| Return | Correlation | |
|---|---|---|
| LXRX | 99.1% | |
| Market (SPY) | 8.7% | 15.6% |
| Sector (XLV) | 5.5% | 17.3% |
Fundamental Drivers
The 142.1% change in LXRX stock from 6/30/2025 to 7/24/2026 was primarily driven by a 123.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302025 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.95 | 2.29 | 142.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 31 | 70 | 123.1% |
| P/S Multiple | 11.0 | 13.2 | 20.0% |
| Shares Outstanding (Mil) | 362 | 400 | -9.5% |
| Cumulative Contribution | 142.1% |
Market Drivers
6/30/2025 to 7/24/2026| Return | Correlation | |
|---|---|---|
| LXRX | 142.1% | |
| Market (SPY) | 20.6% | 23.5% |
| Sector (XLV) | 22.2% | 18.2% |
Fundamental Drivers
The 0.0% change in LXRX stock from 6/30/2023 to 7/24/2026 was primarily driven by a 55172.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.29 | 2.29 | 0.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 70 | 55172.2% |
| P/S Multiple | 3,435.3 | 13.2 | -99.6% |
| Shares Outstanding (Mil) | 189 | 400 | -52.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2023 to 7/24/2026| Return | Correlation | |
|---|---|---|
| LXRX | 0.0% | |
| Market (SPY) | 72.6% | 17.2% |
| Sector (XLV) | 28.2% | 13.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LXRX Return | 15% | -52% | -20% | -52% | 56% | 100% | -33% |
| Peers Return | 28% | 16% | 5% | 8% | 20% | 13% | 129% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| LXRX Win Rate | 42% | 33% | 50% | 42% | 67% | 86% | |
| Peers Win Rate | 55% | 63% | 42% | 50% | 65% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| LXRX Max Drawdown | -63% | -67% | -71% | -82% | -70% | -34% | |
| Peers Max Drawdown | -19% | -18% | -25% | -21% | -25% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LLY, PFE, BMY, JNJ, VRTX. See LXRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/24/2026 (YTD)
How Low Can It Go
| Event | LXRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -60.5% | -18.8% |
| % Gain to Breakeven | 153.3% | 23.1% |
| Time to Breakeven | 95 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -49.2% | -9.5% |
| % Gain to Breakeven | 97.0% | 10.5% |
| Time to Breakeven | 115 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.1% | -33.7% |
| % Gain to Breakeven | 66.9% | 50.9% |
| Time to Breakeven | 245 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -27.9% | -12.2% |
| % Gain to Breakeven | 38.7% | 13.9% |
| Time to Breakeven | 22 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -44.1% | -6.8% |
| % Gain to Breakeven | 78.8% | 7.3% |
| Time to Breakeven | 234 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -24.4% | -0.2% |
| % Gain to Breakeven | 32.2% | 0.2% |
| Time to Breakeven | 508 days | 1 days |
In The Past
Lexicon Pharmaceuticals's stock fell -60.5% during the 2025 US Tariff Shock. Such a loss loss requires a 153.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | LXRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -60.5% | -18.8% |
| % Gain to Breakeven | 153.3% | 23.1% |
| Time to Breakeven | 95 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -49.2% | -9.5% |
| % Gain to Breakeven | 97.0% | 10.5% |
| Time to Breakeven | 115 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.1% | -33.7% |
| % Gain to Breakeven | 66.9% | 50.9% |
| Time to Breakeven | 245 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -27.9% | -12.2% |
| % Gain to Breakeven | 38.7% | 13.9% |
| Time to Breakeven | 22 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -44.1% | -6.8% |
| % Gain to Breakeven | 78.8% | 7.3% |
| Time to Breakeven | 234 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -24.4% | -0.2% |
| % Gain to Breakeven | 32.2% | 0.2% |
| Time to Breakeven | 508 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -52.4% | -17.9% |
| % Gain to Breakeven | 110.3% | 21.8% |
| Time to Breakeven | 134 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -24.1% | -15.4% |
| % Gain to Breakeven | 31.7% | 18.2% |
| Time to Breakeven | 114 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -72.6% | -53.4% |
| % Gain to Breakeven | 264.7% | 114.4% |
| Time to Breakeven | 1232 days | 1085 days |
In The Past
Lexicon Pharmaceuticals's stock fell -60.5% during the 2025 US Tariff Shock. Such a loss loss requires a 153.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of new pharmaceutical products. The company primarily develops orally-delivered small molecule drug candidates aimed at addressing significant medical conditions.
Lexicon's main product pipeline includes Sotagliflozin, which has completed Phase III clinical trials and is being developed for the treatment of heart failure and type 1 diabetes. Additionally, the company has LX9211, currently in Phase II clinical development, targeting neuropathic pain. Lexicon also leverages strategic collaborations and license agreements with major pharmaceutical companies like Bristol-Myers Squibb Company and Genentech, Inc., to advance its development efforts. These products serve markets with substantial unmet medical needs in chronic diseases and pain management.
AI Analysis | Feedback
A mini-Genentech, focused on discovering and developing new drugs.
Like a Moderna or BioNTech, but developing oral small molecule drugs for conditions like heart failure and chronic pain.
An early-stage Vertex Pharmaceuticals, developing its own innovative drugs for specific therapeutic areas.
AI Analysis | Feedback
- Sotagliflozin: An orally-delivered small molecule drug for the treatment of heart failure and type 1 diabetes.
- LX9211: A drug currently in Phase II clinical development for the treatment of neuropathic pain.
AI Analysis | Feedback
Lexicon Pharmaceuticals (LXRX) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of pharmaceutical products. It primarily sells its drug candidates and intellectual property through strategic collaboration and licensing agreements with other pharmaceutical companies.
Based on the provided information, its major customer companies are:
- Bristol-Myers Squibb Company (NYSE: BMY)
- Genentech, Inc. (a subsidiary of Roche Holdings AG; OTC: RHHBY)
AI Analysis | Feedback
AI Analysis | Feedback
Mike Exton, Ph.D. Chief Executive Officer and Director
Mike Exton was appointed Chief Executive Officer of Lexicon Pharmaceuticals in July 2024. He previously spent 14 years at Novartis, where his most recent roles included Cardiometabolism Therapeutic Head and Vice President and Global Head of the Cardiovascular Renal and Metabolism Franchise. Before his tenure at Novartis, Dr. Exton held various positions in research, business development, and commercial operations at Invida Pty Ltd and Eli Lilly Australia. He is recognized for leading the commercialization of a significant heart failure drug, Entresto, and developing a robust cardiometabolic business. Dr. Exton holds a B.Sc. and a Ph.D. in neuroscience from the University of Newcastle, and a Ph.D. in immunology from the University of Essen, Germany.
Scott Coiante Senior Vice President and Chief Financial Officer
Scott Coiante was appointed Senior Vice President and Chief Financial Officer of Lexicon Pharmaceuticals, effective January 2, 2025. He brings over 35 years of experience in finance within the life science and pharmaceutical industries. Prior to joining Lexicon, Mr. Coiante served as Senior Vice President, Chief Financial Officer, and Treasurer of Agile Therapeutics Inc. across two separate tenures, from 2011 to 2019 and from August 2023 to August 2024. He also held the roles of Senior Vice President, Chief Financial Officer, Treasurer, and Secretary at Aprea Therapeutics. Earlier in his career, he held several senior financial positions at Medarex Inc., where he facilitated the company's transition following its acquisition by Bristol-Myers Squibb. Mr. Coiante earned a B.S. in Accounting from Villanova University.
Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer
Brian P. Zambrowicz is a co-founder of Lexicon Pharmaceuticals Inc. He has served as Executive Vice President and Chief Scientific Officer since 2007. Dr. Zambrowicz has been crucial in establishing the company's scientific direction, including the development of its proprietary gene knockout technology and small molecule drug discovery pipeline. His responsibilities include overseeing scientific operations from target discovery to the selection of clinical candidates for both small molecule and antibody therapeutics. He also managed Lexicon's strategic alliances, including those with Bristol-Myers Squibb Company and Genentech, Inc. Before joining Lexicon, Dr. Zambrowicz was an NIH postdoctoral fellow at The Fred Hutchinson Cancer Center. He earned his B.S. in biochemistry from the University of Wisconsin, Madison, and his Ph.D. in biochemistry from the University of Washington, Seattle.
Alan J. Main, Ph.D. Executive Vice President, Commercial Supply Operations
Alan J. Main joined Lexicon Pharmaceuticals in July 2001 as part of the company's acquisition of Coelacanth Corporation. Prior to the acquisition, he served as President and Chief Executive Officer of Coelacanth Corporation, which specialized in proprietary chemistry technologies for drug development. Earlier in his career, Dr. Main spent 20 years at Novartis Pharmaceuticals Corporation as Senior Vice President, U.S. Research. He holds a B.S. from the University of Aberdeen, Scotland, a Ph.D. in organic chemistry from the University of Liverpool, England, and completed postdoctoral studies at the Woodward Research Institute.
Craig Granowitz, MD, PhD Senior Vice President and Chief Medical Officer
Craig Granowitz joined Lexicon as Senior Vice President and Chief Medical Officer, effective August 2, 2021. Before his role at Lexicon, he served as Chief Medical Officer at Amarin Corporation plc. Prior to Amarin, Dr. Granowitz was Senior Vice President and Head of Global Medical Affairs, Global Human Health at Merck & Co., Inc., where he was responsible for establishing a new global medical affairs organization following the merger with Schering-Plough Corporation. At Schering-Plough, he held various medical and commercial management positions, including Group Vice President, Head of Global Medical Affairs, and Senior Vice President of a $2.5 Billion Virology Business Unit. Dr. Granowitz received his B.A. from Dartmouth College and his M.D. and Ph.D. from Columbia University.
AI Analysis | Feedback
The key risks for Lexicon Pharmaceuticals (LXRX) primarily revolve around the inherent challenges of the biopharmaceutical industry, particularly concerning regulatory hurdles, clinical trial outcomes, and financial stability.
- Regulatory Challenges and Pipeline Dependence: Lexicon Pharmaceuticals faces significant regulatory risks, notably demonstrated by the FDA's repeated rejection of sotagliflozin (Zynquista) for type 1 diabetes due to safety concerns, specifically the risk of diabetic ketoacidosis. While sotagliflozin was approved for heart failure (as Inpefa), the company's future remains highly dependent on the successful clinical development and regulatory approval of its other pipeline candidates, such as LX9211 for neuropathic pain. Clinical trial failures or significant delays for these key assets could severely impact the business, and the company may also require partnerships to fund expensive late-stage trials.
- Financial Stability and Cash Runway: As a biopharmaceutical company primarily focused on development, Lexicon Pharmaceuticals currently operates at a loss with negative operating and net margins. The company's financial health is a critical risk factor, with concerns about its cash burn rate and cash runway. While cost reductions and licensing revenues have been implemented, Lexicon faces the ongoing challenge of managing high research and development (R&D) costs and lengthy development cycles, which could necessitate future capital raises and potentially dilute shareholder value.
- Intense Competition: The pharmaceutical sector is highly competitive, especially in therapeutic areas such as cardiometabolic diseases and diabetes, which are central to Lexicon's product portfolio. This intense competition from other pharmaceutical companies, including larger players with greater resources, poses a risk to Lexicon's ability to innovate, achieve market penetration, and maintain favorable market positioning for its approved and pipeline products.
AI Analysis | Feedback
AI Analysis | Feedback
Lexicon Pharmaceuticals, Inc. (LXRX) is focused on developing and commercializing pharmaceutical products for various conditions. The addressable markets for their main product candidates are detailed below:
-
Sotagliflozin (INPEFA) for Heart Failure:
The global heart failure market was valued at over $20 billion in 2023 and is projected to reach approximately $40 billion by 2032. More specifically, the chronic heart failure market size in the 7 Major Markets (7MM), which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was around USD 8 billion in 2023. The U.S. chronic heart failure market alone was approximately USD 5.5 billion in 2023. The advanced heart failure market within the 7MM reached USD 6.50 billion in 2024 and is expected to grow to USD 27.60 billion by 2035. In the United States, the prevalence of heart failure was 6.7 million patients in 2019, with an estimation to reach eight million by 2030. The market for Sotagliflozin specifically (INPEFA) generated a revenue of USD 80.0 million globally in 2024 and is expected to reach USD 108.0 million by 2033. Another report estimates the Sotagliflozin market size at USD 315.75 million in 2024, projected to reach USD 720.40 million by 2032 globally.
-
Sotagliflozin (Zynquista) for Type 1 Diabetes:
The global Type 1 Diabetes market size was estimated at USD 16.01 billion in 2024 and is projected to reach USD 31.48 billion by 2035. Another estimate places the global market at USD 16.97 billion in 2025, expecting it to reach USD 26.22 billion by 2032. The global market size is also reported as USD 37.60 billion in 2025, predicted to increase to approximately USD 79.14 billion by 2035. North America is a dominant region in the global Type 1 Diabetes market, holding an estimated 39.4% market share in 2025 and is expected to lead the global market through 2035. The United States specifically accounts for approximately 89% of the Type 1 Diabetes market share within the 7 Major Markets.
-
LX9211 for Neuropathic Pain:
The global neuropathic pain market was valued at USD 7.7 billion in 2022 and is projected to reach USD 13.3 billion by 2032. Other estimates show the global neuropathic pain market size at USD 5.5 billion in 2023, expected to reach USD 8.1 billion by 2034, or USD 8.59 billion in 2025, increasing to approximately USD 16.79 billion by 2034. Another report states the neuropathic pain market was valued at USD 2.83 billion in 2024 and is poised to grow to USD 4.51 billion by 2033. For diabetic neuropathic pain (DNP), a segment of neuropathic pain, the market across the 7 Major Markets (US, 5EU, and Japan) is expected to grow from USD 1.7 billion in 2021 to USD 3.0 billion in 2031. The global diabetic neuropathy treatment market was estimated at USD 4.34 billion in 2023 and is projected to reach USD 7.28 billion by 2030. In the U.S., approximately 35 million cases of peripheral neuropathic pain were recorded in 2023. The U.S. was the largest market for DNP treatments in 2021, representing 51.4% of global sales, and is expected to continue dominating, reaching USD 2.2 billion by 2031.
AI Analysis | Feedback
Lexicon Pharmaceuticals (LXRX) is expected to experience future revenue growth over the next 2-3 years driven by several key factors:
- Commercialization of Zynquista (sotagliflozin) for Type 1 Diabetes: Lexicon Pharmaceuticals plans to resubmit its New Drug Application (NDA) for Zynquista as an adjunct to insulin in adults with type 1 diabetes in 2026. This resubmission could lead to potential regulatory approval and a subsequent launch, establishing a new significant revenue stream for the company.
- Advancement of Sotagliflozin in Hypertrophic Cardiomyopathy (HCM): The SONATA-HCM Phase 3 clinical trial, evaluating sotagliflozin for the treatment of hypertrophic cardiomyopathy, is on track to complete enrollment by mid-2026, with top-line results anticipated in the first quarter of 2027. Positive outcomes from this pivotal trial would pave the way for a potential new indication and market expansion for sotagliflozin.
- Progress and Potential Partnership for LX9211 (pilavapadin) in Diabetic Peripheral Neuropathic Pain (DPNP): Lexicon is advancing LX9211 into late-stage development for diabetic peripheral neuropathic pain. Following positive top-line data from the Phase 2b PROGRESS study (anticipated Q1 2025), successful progression to Phase 3, potentially with a development partner, would bring this candidate closer to commercialization and contribute to future revenue growth.
- Milestone Payments and Future Royalties from LX9851 Collaboration with Novo Nordisk: Lexicon has an exclusive licensing agreement with Novo Nordisk for LX9851 in obesity and related disorders. The company received a $10 million milestone payment in February 2026 and has the potential to earn up to an additional $20 million in milestones in 2026, along with tiered royalties on net sales of LX9851. These payments will contribute to Lexicon's revenue.
- Growth in INPEFA (sotagliflozin) Sales for Heart Failure: INPEFA, an orally-delivered small molecule drug, is already commercialized for heart failure. Continued efforts in its commercialization and market penetration are expected to drive growth in net product sales, contributing to Lexicon's overall revenue.
AI Analysis | Feedback
Share Issuance
- In January 2026, Lexicon Pharmaceuticals successfully priced a public offering of 32 million shares at $1.30 each, raising $41.6 million.
- Concurrently in January 2026, the company arranged a private placement with Invus, L.P., its largest shareholder, which is expected to generate an additional $41.1 million through the sale of common shares and Series B convertible preferred stock.
- In March 2024, Lexicon completed a private investment in public equity (PIPE) financing, raising approximately $250 million through the sale of Series A convertible preferred stock to a group of accredited investors, including an affiliate of Invus, L.P.
Inbound Investments
- In March 2025, Lexicon entered into an exclusive licensing agreement with Novo Nordisk for LX9851, an obesity drug candidate, which included a $45 million upfront payment received in April 2025.
- A $10 million milestone payment from Novo Nordisk for LX9851 was triggered in January 2026.
- The company received a $25 million upfront payment in 2024 from Viatris for sotagliflozin licensing.
Capital Expenditures
- Lexicon Pharmaceuticals' capital expenditures were $1.0 million in 2025.
- Research and development (R&D) expenses were $61.1 million in 2025, a decrease from $84.5 million in 2024.
- Expected R&D expenses for 2026 are projected to be between $63 million and $68 million, primarily focused on the continued research, development, and commercialization of drug candidates such as sotagliflozin and LX9851.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 162.75 |
| Mkt Cap | 133.1 |
| Rev LTM | 55,898 |
| Op Inc LTM | 14,550 |
| FCF LTM | 9,926 |
| FCF 3Y Avg | 5,290 |
| CFO LTM | 12,645 |
| CFO 3Y Avg | 11,337 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.1% |
| Rev Chg 3Y Avg | 7.9% |
| Rev Chg Q | 7.2% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Inc Chg LTM | 73.0% |
| Op Inc Chg 3Y Avg | 44.2% |
| Op Mgn LTM | 27.4% |
| Op Mgn 3Y Avg | 22.2% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 27.8% |
| CFO/Rev 3Y Avg | 20.4% |
| FCF/Rev LTM | 18.8% |
| FCF/Rev 3Y Avg | 15.9% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA216203 | INPEFA | sotagliflozin | tablet | 5262023 | -42.5% | -64.5% | -49.1% | -79.2% | -28.0% |
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA216203 | INPEFA | sotagliflozin | tablet | 5262023 | -42.5% | -64.5% | -49.1% | -79.2% | -28.0% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovery, development and commercialization of pharmaceutical products for the treatment of human | 50 | 31 | 1 | 0 | 0 |
| Total | 50 | 31 | 1 | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Discovery, development and commercialization of pharmaceutical products for the treatment of human | -49 | -197 | -172 |
| Total | -49 | -197 | -172 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Discovery, development and commercialization of pharmaceutical products for the treatment of human | -50 | -200 | -177 |
| Total | -50 | -200 | -177 |
Price Behavior
| Market Price | $2.29 | |
| Market Cap ($ Bil) | 0.9 | |
| First Trading Date | 04/07/2000 | |
| Distance from 52W High | -13.3% | |
| 50 Days | 200 Days | |
| DMA Price | $2.14 | $1.64 |
| DMA Trend | up | up |
| Distance from DMA | 6.8% | 39.9% |
| 3M | 1YR | |
| Volatility | 77.0% | 78.3% |
| Downside Capture | -70.05 | 102.85 |
| Upside Capture | 87.53 | 167.39 |
| Correlation (SPY) | 0.8% | 22.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.58 | 0.00 | 0.66 | 1.05 | 1.65 | 1.20 |
| Up Beta | 2.63 | 0.86 | 1.32 | 1.47 | 1.64 | 0.83 |
| Down Beta | 1.21 | 1.05 | -0.34 | 0.83 | 1.21 | 1.13 |
| Up Capture | -145% | 81% | 139% | 206% | 448% | 318% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 12 | 23 | 33 | 63 | 119 | 335 |
| Down Capture | -283% | -261% | -42% | 24% | 122% | 110% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 7 | 16 | 26 | 51 | 116 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LXRX | |
|---|---|---|---|---|
| LXRX | 89.7% | 78.5% | 1.14 | - |
| Sector ETF (XLV) | 20.9% | 15.7% | 1.02 | 18.3% |
| Equity (SPY) | 17.6% | 12.7% | 1.00 | 22.4% |
| Gold (GLD) | 19.2% | 28.1% | 0.61 | 18.2% |
| Commodities (DBC) | 34.7% | 19.1% | 1.42 | 5.6% |
| Real Estate (VNQ) | 13.8% | 14.1% | 0.69 | 12.8% |
| Bitcoin (BTCUSD) | -45.4% | 42.9% | -1.29 | 19.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LXRX | |
|---|---|---|---|---|
| LXRX | 0.7% | 96.4% | 0.46 | - |
| Sector ETF (XLV) | 6.4% | 15.0% | 0.25 | 20.6% |
| Equity (SPY) | 12.8% | 17.1% | 0.58 | 25.3% |
| Gold (GLD) | 17.0% | 18.4% | 0.75 | 8.0% |
| Commodities (DBC) | 9.6% | 19.5% | 0.38 | 2.6% |
| Real Estate (VNQ) | 3.0% | 18.9% | 0.06 | 21.2% |
| Bitcoin (BTCUSD) | 15.7% | 53.4% | 0.47 | 16.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LXRX | |
|---|---|---|---|---|
| LXRX | -12.4% | 96.6% | 0.31 | - |
| Sector ETF (XLV) | 10.0% | 16.6% | 0.49 | 19.5% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 21.6% |
| Gold (GLD) | 11.3% | 16.1% | 0.57 | 4.0% |
| Commodities (DBC) | 7.2% | 17.9% | 0.32 | 5.6% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 15.9% |
| Bitcoin (BTCUSD) | 58.3% | 66.2% | 0.98 | 9.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 5.0% | 52.5% | 19.4% |
| 3/5/2026 | 0.6% | 5.5% | -2.5% |
| 11/6/2025 | 3.6% | 11.6% | 0.7% |
| 8/6/2025 | 9.5% | 1.0% | 1.9% |
| 5/13/2025 | -15.6% | -9.5% | 10.4% |
| 3/6/2025 | 6.6% | -2.9% | 13.9% |
| 11/12/2024 | -8.4% | -26.0% | -30.9% |
| 8/1/2024 | -16.1% | -16.8% | -14.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 11 | 15 |
| # Negative | 10 | 13 | 9 |
| Median Positive | 5.8% | 11.2% | 7.8% |
| Median Negative | -8.6% | -10.4% | -14.4% |
| Max Positive | 29.5% | 52.5% | 32.8% |
| Max Negative | -27.4% | -26.0% | -30.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 5.0% | 52.5% | 19.4% |
| 3/5/2026 | 0.6% | 5.5% | -2.5% |
| 11/6/2025 | 3.6% | 11.6% | 0.7% |
| 8/6/2025 | 9.5% | 1.0% | 1.9% |
| 5/13/2025 | -15.6% | -9.5% | 10.4% |
| 3/6/2025 | 6.6% | -2.9% | 13.9% |
| 11/12/2024 | -8.4% | -26.0% | -30.9% |
| 8/1/2024 | -16.1% | -16.8% | -14.4% |
| 5/2/2024 | 2.4% | 11.2% | 2.9% |
| 3/11/2024 | 29.5% | 19.8% | -4.6% |
| 11/8/2023 | -8.8% | -10.4% | 0.0% |
| 8/3/2023 | -2.6% | -10.4% | -12.0% |
| 5/2/2023 | 15.1% | 27.3% | 13.9% |
| 3/2/2023 | 22.9% | 3.7% | 11.5% |
| 11/9/2022 | 14.3% | 16.8% | 4.1% |
| 8/2/2022 | 3.5% | -1.5% | 5.8% |
| 5/5/2022 | -4.6% | -16.0% | -6.7% |
| 2/28/2022 | -27.4% | -25.3% | -27.0% |
| 11/3/2021 | -13.9% | -15.8% | -27.7% |
| 8/2/2021 | 3.1% | 0.6% | 27.7% |
| 5/6/2021 | 2.7% | -5.8% | 7.8% |
| 3/10/2021 | -4.8% | -9.7% | -26.4% |
| 10/29/2020 | -4.9% | -11.5% | 32.8% |
| 7/30/2020 | 14.9% | 10.3% | 1.1% |
| SUMMARY STATS | |||
| # Positive | 14 | 11 | 15 |
| # Negative | 10 | 13 | 9 |
| Median Positive | 5.8% | 11.2% | 7.8% |
| Median Negative | -8.6% | -10.4% | -14.4% |
| Max Positive | 29.5% | 52.5% | 32.8% |
| Max Negative | -27.4% | -26.0% | -30.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/10/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 03/12/2021 | 10-K |
| 09/30/2020 | 10/30/2020 | 10-Q |
| 06/30/2020 | 07/29/2020 | 10-Q |
| 03/31/2020 | 04/27/2020 | 10-Q |
| 12/31/2019 | 03/12/2020 | 10-K |
| 09/30/2019 | 11/07/2019 | 10-Q |
| 06/30/2019 | 08/01/2019 | 10-Q |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Milestone Payment | 10.00 Mil | -50.0% | Lowered | Guidance: 20.00 Mil for 2026 | |||
Prior: Q4 2025 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 LX9851 Milestone Payments | 20.00 Mil | ||||||
Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Milestone Payments | 30.00 Mil | 0 | Affirmed | Guidance: 30.00 Mil for 2025 | |||
Insider Activity
Updated 6/4/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Debbane, Raymond | Direct | Buy | 2272026 | 1.49 | 2,000 | 2,980 | 2,840,217 | Form | |
| 2 | Debbane, Raymond | Direct | Buy | 2252026 | 1.47 | 100,000 | 147,000 | 2,799,153 | Form | |
| 3 | Debbane, Raymond | Direct | Buy | 2232026 | 1.48 | 100,000 | 147,790 | 2,666,406 | Form | |
| 4 | Debbane, Raymond | Direct | Buy | 2232026 | 1.44 | 50,000 | 71,965 | 2,452,835 | Form | |
| 5 | Debbane, Raymond | Direct | Buy | 2182026 | 1.32 | 133,688 | 176,468 | 2,183,526 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Debbane, Raymond | Direct | Buy | 2272026 | 1.49 | 2,000 | 2,980 | 2,840,217 | Form | |
| 2 | Debbane, Raymond | Direct | Buy | 2252026 | 1.47 | 100,000 | 147,000 | 2,799,153 | Form | |
| 3 | Debbane, Raymond | Direct | Buy | 2232026 | 1.48 | 100,000 | 147,790 | 2,666,406 | Form | |
| 4 | Debbane, Raymond | Direct | Buy | 2232026 | 1.44 | 50,000 | 71,965 | 2,452,835 | Form | |
| 5 | Debbane, Raymond | Direct | Buy | 2182026 | 1.32 | 133,688 | 176,468 | 2,183,526 | Form | |
| 6 | Debbane, Raymond | Direct | Buy | 2182026 | 1.31 | 76,857 | 100,544 | 1,989,115 | Form | |
| 7 | Debbane, Raymond | Direct | Buy | 2182026 | 1.31 | 57,952 | 75,877 | 1,890,159 | Form | |
| 8 | Invus, Global Management, Llc | See Footnotes | Buy | 2042026 | 1.30 | 1,538,462 | 2,000,001 | 2,000,001 | Form |
Investor Activity (13F)
Updated Jul 25, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.